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Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic component of 
the metabolic syndrome and its prevalence is rapidly increasing due its strong 
association with insulin resistance and obesity. At present, given than NAFLD is highly 
prevalent and therapies are limited, much attention is focussed on identifying effective 
dietary strategies for the prevention and treatment of the disease. Polyphenols are a 
group of plants bioactive compounds whose regular consumption have been associated 
with a reduction in the risk of a number of metabolic disorders associated with NAFLD. 
Here, we review the emerging and relatively consistent evidence from cell culture and 
rodent studies showing that select polyphenols positively modulate a variety of 
contributors to the NAFLD phenotype, through diverse and complementary 
mechanisms of action. In particular, the reduction of de novo lipogenesis (via SREBP-
1c) and increased fatty acid β-oxidation, presumably involving AMPK activation, will 
be discussed. The antioxidant and anti-inflammatory properties of polyphenols which 
have been reported to contribute to the amelioration of NAFLD will also be addressed. 
In addition to a direct study of the liver, rodent studies have provided insight into the 
impact of polyphenols on adipose tissue function and whole body insulin sensitivity, 
which are likely to in part modulate their impact on NAFLD development. Finally an 
overview of the limited data from clinical trials will be given along with a discussion of 
the dose extrapolation from animal studies to humans. 
 
Flavonoids: Steatosis: SREBP-1c: PPARα: Insulin resistance: Obesity 
Introduction 
 
The term “non-alcoholic fatty liver disease” (NAFLD) refers to a condition defined by 
ectopic fat accumulation in the form of triglycerides (TG) in the liver, when it accounts 
for more than 5% of total organ weight. NAFLD encompasses a wide spectrum of liver 
damages, ranging from simple TG accumulation in hepatocytes (steatosis) to non-
alcoholic steatohepatitis (NASH), which is characterised by the additional presence of 
inflammation and tissue injury(1,2). NASH can lead to fibrosis, which can progress to 
cirrhosis with a high risk of liver failure and hepatocellular carcinoma(3). NAFLD is a 
major public health issue in Western industrialized countries(3), with an estimated 
prevalence in the general population of 20% - 30%(2). Most NAFLD patients are 
clinically asymptomatic with approximately 10-25% progressing to NASH and 5-8% of 
those will be susceptible to develop cirrhosis within five years. Furthermore, Milic et 
al., reported that 12.8% of patients with liver cirrhosis will develop hepatocellular 
carcinoma within 3 years(4). 
NAFLD is considered to be the hepatic component of the metabolic syndrome (MS), 
which is characterised by insulin resistance, obesity (>90% of NAFLD patients are 
overweight), hyperinsulinemia, dyslipidaemia and hypertension(3,5,6). NAFLD has 
emerged as a significant risk factor for CVD, which is the most prevalent clinical 
feature of NAFLD(6). 
Although a persistent elevation of plasma transaminase enzymes can be used as an early 
indication of liver damage, the accurate diagnosis of NAFLD presence and severity is 
not possible by routine blood tests. For an accurate and sensitive diagnosis of 
NAFLD/NASH a liver biopsy accompanied by histological staining and NAFLD 
activity scoring (NAS) is considered the gold standard, but its use in clinical practice is 
limited by its invasive nature(2,7,8).  
At present, NAFLD due to its high prevalence and pathological consequences, 
represents an important economic burden for European countries(9). However, to date, 
there is no licensed medication or surgical procedure for NAFLD. Lifestyle strategies 
such as dietary and exercise regimens focussed on weight reduction and insulin 
sensitisation have been the primary therapeutic approach(3). Although these strategies 
have been shown to be efficacious in randomised controlled trials, at a population level, 
due to poor compliance, they have had a limited impact on NAFLD incidence and 
severity(3). Therefore there is a great need to identify effective approaches for NAFLD 
management. 
Polyphenols are found ubiquitously in plants and their regular consumption has been 
associated with a reduction in the risk of a number of metabolic diseases, including 
obesity, insulin resistance, hypertension and CVD(10,11). New evidence supports the idea 
that a polyphenol-rich diet may have an important role in the prevention and treatment 
of NAFLD. The purpose of the present review is to highlight the efficacy of 
polyphenols in NAFLD and discuss the key molecular mechanisms which modulate 
their potential clinical benefits.  
 
NAFLD pathophysiology  
 
NAFLD has a complex pathophysiology, which is described by the “two-hit 
hypothesis”(7). In this model, the first hit describes the accumulation of fatty acids (FA) 
and TG in hepatocytes leading to steatosis, which results from multiple mechanisms 
such as: a) increased hepatic delivery and uptake of FA associated with increased 
lipolysis in visceral and subcutaneous adipose tissue and/or increased intake of dietary 
fat, b) decreased FA oxidation, c) increased hepatic de novo lipogenesis, and d) 
decreased hepatic lipid export via VLDL(7,12). The inability to regulate lipid partitioning 
leads to the second hit, whereby an overwhelmed FA β-oxidation produces 
mitochondrial dysfunction which increases reactive oxygen species (ROS) resulting in 
sustained oxidative stress and a depletion of the antioxidant defences(13,14). FA 
intermediates and a compromised oxidative status activates Kupffer cells producing 
inflammatory mediators, and dysregulated insulin action leading to the progression from 
benign steatosis to NASH(3,13). Finally, chronic inflammation and oxidative stress 
induce hepatocytes apoptosis and injury which activates stellate cells which are central 
to the progression to liver fibrosis(3,14). 
 
Polyphenols: Chemical structures and sources  
 
Phenolic compounds are secondary metabolites of plants which are present in high 
amounts in fruits, vegetables, cereals and beverages such as red wine, tea or coffee. 
More than 8000 structures have been identified ranging from compounds with at least 
one aromatic ring with one or two hydroxyl groups, to polymers of up to 50 units with 
multiple hydroxyl groups. Generally, all phenolic compounds are commonly referred to 
as polyphenols, despite a group of them having only one aromatic ring. These 
compounds are divided into two main categories, namely flavonoids and non-
flavonoids, based on the number of phenols rings and the way in which these rings 
interact(15). 
Flavonoids have a common basic structure of 15 carbons (C6-C3-C6) with two aromatic 
carbon rings (A and B rings) connected by a three-carbon bridge (C ring). Flavonoids 
may be sub-classified according to the degree of oxidation of the C-ring, the 
hydroxylation pattern of the ring structure and the substitution of the 3-position into: a) 
flavonols (e.g., quercetin, kaempferol) whose sources include onions and broccoli, b) 
flavones (e.g., luteolin, apigenin) found in celery and parsley, c) isoflavones (e.g., 
genistein and daidzein) found in leguminous plants and in particular soybeans and soy 
products, d) flavanones (e.g., naringerin, hesperitin) abundant in citrus fruits, wine and 
herbs such as oregano, e) anthocyanidins (e.g., cyanidin, peonidin) found in berry fruits 
and red wine, and f) flavanols (e.g., (+)-catechin, (-)-epicatechin, epigalocatechin) 
abundant in cocoa and green tea(11,15) (Figure 1). 
Non-flavonoids may be sub-classified into phenolic acids and stilbenes. Phenolic acid 
includes hydroxybenzoic acid (C6-C1) and hydroxycinnamic acids (C6-C3). 
Hydroxybenzoic acids (e.g., gallic acid, ellagic acid) are found in pomegranate and 
raspberries. Hydroxycinnamic acids (e.g., caffeic acid) can be found in coffee beans and 
blueberries. Stilbenes have a C6-C3-C6 structure. Resveratrol which is the main stilbene, 
can be found as cis or trans isomers as well as conjugated derivatives in grapes and red 
wine(11,15) (Figure 1). 
Polyphenols have been identified as powerful antioxidants in vitro(16). However given 
their extensive metabolism and relatively low tissue concentrations, their in vivo 
preventative properties are considered largely independent of conventional antioxidant 
activities(16). The ability of polyphenols to exert antioxidant properties in vivo depends 
on the extent of their phase 1 and 2 biotransformation and conjugation during 
absorption in the gastrointestinal tract and post-absorption primarily in the liver. 
Although a full overview of polyphenols metabolism and its regulation is beyond the 
scope of the current review (see Rodriguez-Mateos et al.(11) for an extensive review), 
knowledge about their bio-kinetics (the composite of their distribution, 
biotransformation and elimination), alluded to throughout, is essential to understand the 
bioactivity of polyphenols in vivo(11). 
In vitro studies 
 
Cell culture studies constitute a useful tool to elucidate the molecular mechanisms of 
action of polyphenols in the prevention of steatosis. Primary cultures of human 
hepatocytes are the optimal model for studying determinants of NAFLD. However their 
widespread use is limited by logistical factors such as liver samples availability. The 
main alternative model is the human hepatocyte-derived cell line, HepG2.  
Palmitic (16:0) and oleic (18:1n9) acids are the most abundant FA in the liver of both 
normal subjects and NAFLD patients(17) and have been used (generally in a bovine 
serum complex) to induce lipid accumulation in HepG2 and reproduce the key cellular 
features of human NAFLD(17,18,19). In addition, steatosis in HepG2 cells has been 
induced by high concentrations of glucose (25-30mM)(20,21) which through a multistep 
process including glycolysis and the Krebs Cycle generates acetyl-CoA, a key substrate 
for de novo lipogenesis(7).  
Pure polyphenols compounds and polyphenol-rich extracts have been tested in both 
these in vitro models of steatosis (Table 1). Most studies are concordant with the fact 
that a range of polyphenols reduce hepatocellular TG accumulation induced by fatty 
acids(18,19,22,23,24) or by high glucose concentrations(20,21,25) with a range of reported 
mechanisms including an inhibition of lipogenesis and a promotion of FA catabolism 
(Figure 2).  
Sterol regulatory element-binding protein 1c (SREBP-1c) is the most important 
transcription factor regulating genes involved in fatty acid synthesis and TG metabolism 
in the liver(26). A number of in vitro studies with polyphenols, have shown a down-
regulation of SREBP-1c and its main targets in lipogenesis(20,22,24). In particular, Liu, et 
al.(22) reported that luteolin induced a reduction of palmitate-stimulated lipid 
accumulation in HepG2 cells associated with decreased SREBP-1c and fatty acid 
synthase (FAS) gene expression and an attenuation of the activity of acetyl-coenzyme A 
carboxylase (ACC). ACC and FAS play an essential role in de novo lipogenesis 
converting the acetyl-CoA into palmitate that subsequently is esterified into TG in the 
liver. Similar reduced expression of SREBP-1c and FAS were reported using a 
chlorogenic acid derivate (3-caffeoyl, 4-dihydrocaffeoylquinic acid) and rutin 
(quercetin-3-O-rutinoside) in a high glucose-stimulated and oleic-stimulated lipid 
accumulation HepG2 cell model respectively(20,24). In addition, treatment with 3-
caffeoyl, 4-dihydrocaffeoylquinic acid, luteolin and rutin induced an activation (by 
phosphorylation) of the adenosine monophosphate-activated protein kinase (AMPK), a 
well-known inhibitor of SREBP-1c and hence of lipogenesis(20,22,24). Sirtuin 1 (SIRT-1) 
activation by polyphenols represents a downstream regulator of AMPK(27). Pil et al(20) 
found that 3-caffeoyl, 4-dihydrocaffeoylquinic acid treatment increased SIRT-1 activity, 
suggesting that SIRT-1 may be involved in the AMPK-dependent reduction in SREBP-
1c and FAS expression induced by polyphenols. Cyanidin-3-O-β-glucoside (C3G) also 
attenuated de novo lipogenesis through an alternative pathway, increasing PKC ζ 
activity and suppressing mitochondrial glycerol-3-phosphate acyltransferase 1 
(mtGPAT1) activation, the rate limiting enzyme which controls the first step of TG 
synthesis from palmitate(25). 
In the liver, PPARα plays a pivotal role in FA metabolism by up-regulating the 
expression of numerous genes involved in FA oxidation as well as numerous other 
processes which regulate cellular FA status such as receptor mediated FA uptake and 
lipoprotein assembly and secretion(28). As a consequence, activation of PPARα is 
associated with decreased hepatic fat storage(7). Oxidation of FAs occurs within the 
mitochondria, peroxisomes and the endoplasmic reticulum (ER) and is regulated mainly 
through key rate limiting enzymes such as carnitine palmitoyl transferase 1 (CPT1) and 
acyl-CoA oxidase (ACO). In the outer membrane of mitochondria, CPT1 mediates the 
transfer of FAs from the cytosol into the mitochondria prior to β-oxidation and ACO 
catalyses the first rate limiting step in peroxisomal β-oxidation(7,13). Procyanidin B1 (an 
epicatechin-(4β→8)-catechin dimer) suppressed palmitic-stimulated lipid accumulation 
in HepG2 cells through an up-regulation of the ACO and CPT1 mRNA expression(19). 
In addition to inhibiting lipogenesis, luteolin, induced CPT1 gene expression in HepG2 
challenged with palmitate(22). Furthermore, rutin increased PPARα protein levels which 
was associated with a reduction in the lipid load in HepG2 cells(24). 
It is well known that a number of polyphenols can indirectly act as antioxidants by 
inducing phase II antioxidant defences enzymes(29,30,31). There is evidence suggesting 
that the antioxidant response can alleviate the cellular damage induced by oxidative 
stress during the progression of NAFLD(14). Accordingly, Vidyashankar et al.(18) 
reported that quercetin induced an increase in the activity of antioxidant cellular 
defences, such as catalase (CAT), glutathione peroxidase (GPx) and superoxide 
dismutase (SOD) and an increase of reduced glutathione (GSH) levels. Likewise, rutin 
attenuated the cellular oxidative stress induced by oleic acid through raised SOD, GPx 
and CAT protein levels which was associated with an increase in PPARα protein 
levels(24). A sustained oxidative stress can induce hepatocyte apoptosis and accentuate 
the transition from simple steatosis to NASH. Jiang et al., showed that C3G reduced 
oxidative stress and the apoptotic pathway activation induced by hyperglycaemia 
preventing mitochondrial dysfunction through modulation of PI3K/AKT and JNK 
signalling pathways (32). 
 
Animal in vivo studies 
 
Animal models of NAFLD can be divided in three major categories: those caused by a 
genetic mutation, by a dietary or pharmacological manipulation or a combination of 
both models(33). The choice of model results in variability in the characteristics and 
severity of the NAFLD phenotype and its aetiological basis, with careful selection 
needed in order to address the specific research question in a meaningful way. For 
example, two of the most widely used dietary models of NASH, the high fat diet (HFD) 
and the methionine and choline deficiency (MCD) display important differences in their 
metabolic characteristics. Although both models present significant steatosis, mice fed a 
HFD develop obesity and insulin resistance which are characteristic of NAFLD and 
NASH in humans. In the other hand, mice fed a MCD exhibit atypical (for humans) 
weight loss and low serum insulin and leptin levels. However, the MCD model 
produces a more pathological form of NAFLD characterised by severe inflammation, 
oxidative stress, mitochondrial dysfunction, apoptosis and fibrogenesis features which 
are only induced to a limited extent when using the HFD model(33). For evaluation of 
the efficacy of dietary approaches in NAFLD, the HFD may be chosen when evaluating 
the ability to prevent NAFLD development or for ameliorating steatosis, whereas the 
MCD model may be more appropriate to assess the therapeutic potential to reverse 
NASH associated liver injury.  
Several studies have revealed that different subclasses of polyphenols ameliorate the 
severity and metabolic consequences of NAFLD in animal models. In general, liver 
biopsies (using haematoxylin/eosin staining) accompanied by semi-quantitative NAS 
scoring have shown that pure polyphenols or polyphenolic extracts reduced liver TG 
accumulation(34,35,36,37,38). However, the underlying molecular mechanisms associated 
with reduced steatosis are variable and dependant on the choice of animal model and the 
dose of phenolic compound of interest (Table 2 and Figure 2). 
 
Adipokine amelioration: NAFLD has been correlated with visceral adiposity and 
dysregulation of a variety of adipokines(39). Increased serum leptin levels are found in 
NAFLD patients and are correlated with the severity of hepatic steatosis(40). 
Adiponectin has been recently reported to hamper the excess lipid storage in the liver 
and decreased levels of this adipokine are observed in NASH patients(41). In HFD-fed 
mice, dietary intake of the isoflavone genistein has been shown to reduce hepatic 
steatosis and adiposity. This “anti-obesity” effect has been associated with a modulation 
of adipokines gene expression, reducing leptin levels and increasing adiponectin levels 
in the adipose tissue(42). Likewise, in the HFD-fed mice model, polyphenol-rich grape 
extract supplementation ameliorated abnormal plasma leptin and adiponectin levels 
which were associated with a reduction in NEFA(43). Collectively these results suggest 
that polyphenols could partially prevent the hepatic steatosis associated with obesity 
through improved regulation of adipokines.  
 
Improvement of insulin sensitivity and de novo lipogenesis reduction: Postprandial 
insulin secretion promotes hepatic glucose uptake, glycogen synthesis, inhibits 
gluconeogenesis and stimulates de novo lipogenesis through SREBP-1c activation(13). In 
obese-hyperinsulinemic mice, insulin signalling fails to decrease gluconeogenesis but 
still stimulates lipogenesis through SREBP-1c up-regulation, producing liver 
hypertriglyceridemia and hyperglycemia(44). Using different NAFLD rodent models, 
resveratrol, genistein and an anthocyanin rich Hibiscus sabdariffa L. extract (HSE) have 
been shown to reduce insulin levels(21,38,45) along with reducing de novo lipogenic gene 
and protein expression and their master regulator SREBP-1c (38,42,43,45,46,47). In addition, 
in nSREBP-1c transgenic C57/BL6 male mice, which show severe insulin resistance 
and develop NASH, a epigallocatechin-3-gallate supplement improved insulin 
sensitivity and promoted the functional recovery of insulin receptor substrate-1 (IRS-
1)(34).  
 
Enhancement of β-fatty acid oxidation: An imbalance between lipogenesis and fatty 
acid oxidation is central to the development and progression of steatosis/NASH. In this 
regard, an increase in the liver SREBP-1c/PPAR-α ratio, due to an up-regulation of 
SREBP-1c and/or down-regulation of PPAR-α, has been proposed to favour the 
development of steatosis in obese patients with NAFLD(48). In mice fed a HFD, 
anthocyanin-rich juice supplementation stimulated PPAR-α up-regulation in parallel 
with a down-regulation of de novo lipogenic genes expression in the liver(49). 
Supplementation with isoflavones reduced liver steatosis by up-regulating genes 
involved in fatty acid β-oxidation and down-regulating genes associated with 
lipogenesis in the adipose tissue(42). Vitaglione et al.(50) have also reported an up-
regulation of PPAR-α gene expression and a higher rate of β-oxidation in the liver of 
rats with NASH supplemented with coffee polyphenols extract as a mechanism to 
reduce fat deposition in the liver. In addition, resveratrol supplementation in rats fed a 
high fat-high sucrose diet activated PPAR γ coactivator 1α (PGC1-α), a co-factor of 
PPAR-α in the induction of mitochondrial oxidative metabolism, associated with an 
increase in β-fatty acid oxidation(51)  
 
AMPK as a key regulator in NAFLD prevention: There is evidence that activation of 
AMPK is a central target for the effects of polyphenols in metabolic disorders related to 
NAFLD(52). Consistent with this assumption, Beltran-Debón et al.(38,53) have 
demonstrated that HSE and Rooibos extracts can prevent steatosis through AMPK 
activation in LDL receptor deficient mice (LDLr -/-) fed a high fat-high cholesterol diet. 
Similarly, other studies have reported that the preventative effect of resveratrol in liver 
fat accumulation, through up-regulation of fatty acid oxidation and down-regulation of 
lipogenesis, was at least in part mediated by the activation of the AMPK/SIRT-1 
axis(21,51). It has also been reported that AMPK in the liver enhances the ratio between 
β-oxidation and lipogenesis, via SREBP-1c down-regulation(54) and a promotion of 
mitochondrial content and function(27). Furthermore, AMPK stimulates β-fatty acid 
oxidation indirectly through inhibition of ACC which synthetises malonyl-CoA from 
acetyl-CoA(55). Malonyl-CoA has been described as an allosteric inhibitor of CPT-1(56). 
Therefore, ACC inactivation by AMPK reduces TG synthesis but also enhances the 
fatty acids influx to the mitochondria for β-fatty acid oxidation(55). In consequence, the 
activation of AMPK by polyphenols has emerged as an important target in the 
prevention of NAFLD. 
 
Antioxidant defences mechanisms prevent NAFLD progression: NAFLD is 
characterised by oxidative stress and a redox imbalance generated in part as a 
consequence of insulin resistance and an accumulation of FA in hepatocytes(3,13). 
Elevated free radicals, lipid peroxidation and reduced antioxidants have been observed 
in NAFLD patients and animals models(13). Nuclear factor-erythroid 2-related factor 2 
(Nrf2) is the main transcription factor which maintains cellular redox status through 
downstream modulation of antioxidant defences genes(14).  It has been recently reported 
that Nrf2 knockout mice (Nrf2-/-) fed a HFD developed a more severe steatosis and 
inflammation than wild type Nrf2 mice(57,58) which indicates the hepato-protective role 
of Nrf2. It is widely accepted that numerous polyphenols can activate Nrf2 which in 
turn, induces a variety of antioxidant defence enzymes which would result in reduced 
oxidative stress(29,30). Consistent with this statement, supplementation with quercetin, 
resveratrol and genistein have been reported to reduce lipid peroxidation in both the 
liver(35,36,37,59,60) and serum(35) of NAFLD animals. Gomez-Zorita et al.(37) also reported 
a raised GSH/GSSG ratio level and Bujanda et al.(60) an increase in the CAT, SOD and 
GPx enzymatic activities in the liver of the NAFLD animals fed with resveratrol.  
 
Anti-inflammatory effect preventing NAFLD onset and progression: Inflammation is 
one of the main hallmarks of the progression from steatosis to NASH. It has been 
proposed that obesity promotes a systemic chronic low-grade inflammation which 
contributes to the development of metabolic disorders such as NAFLD(4). TNF-α and 
IL-6 are two of the main pro-inflammatory cytokines involved in the onset and 
progression of NAFLD which are secreted initially in the adipose tissue and later in the 
liver by Kupffer cells(5,39). It has been described that interaction of TNF-α with its 
receptor (TNFR) inhibits insulin receptors and activates NF-κB transcription factor and 
JNK pathways(12). In addition increased hepatic and circulating TNF-α and IL-6 levels 
have been observed in patients with NAFLD(7,12). Recently, it has been proposed that a 
HFD can alter gut microbiota speciation and metabolism which e.g. via alterations in 
LPS production can influence not only gastrointestinal but also systemic 
inflammation(61). In rodent models supplementation with different polyphenols reduced 
the inflammatory profile in the serum/liver induced by HFD or MCD contributing to the 
amelioration of fatty liver dysfunction(35,46,50,59,62). In particular, studies using genistein, 
quercetin and resveratrol suggested that this anti-inflammatory effect was achieved 
through the repression of NF-κB translocation or gene expression(35,46,62) as well as a 
diminution in the JNK phosphorylation protein levels(35,62). Adiponectin is also involved 
in the anti-inflammatory response(7,39). Then, the enhanced adiponectin secretion and 
gene expression induced by polyphenol-rich grape extract(43) and genistein(42) (see 
above) may also contribute to reduced hepatic inflammation and ultimately the 
progression of NAFLD.  
 Clinical trials 
 
To the best of our knowledge, only five human randomised controlled trials (all with a 
double-blinded placebo-controlled design) focused on polyphenols and NAFLD have 
been published to date (Table 3). Three were undertaken with 500mg and 600mg of 
resveratrol for 12 weeks(63,64) or 3000mg for 8 weeks(65). The other two studies were 
carried out using a HSE (about 150 mg of polyphenols)(66) or a bayberry juice (500mL 
equivalent to 1350 mg of polyphenols)(67) for 12 and 4 weeks respectively. Four out of 
the five studies have reported a significant impact of intervention on select 
characteristics of NAFLD. Chang et al., reported that anthropometric characteristics 
(body weight, body mass index and waist/hip ratio) were significantly lower (1.4%, 
1.33% and 1.09% respectively) following intervention with HSE(66) but no changes 
were observed with bayberry juice(67). For the two clinical trials using a similar dose of 
resveratrol (500 and 600mg) only one observed a reduction in anthropometric 
measurements. This apparent discrepancy is likely due to the fact that in one of the trials 
resveratrol intervention was accompanied with a change in lifestyle with patients 
advised to follow physical activity guidelines(63). With regard to hepatic function, two of 
the resveratrol interventions reduced the alanine transaminase liver enzyme (ALT) in 
serum by 15%(63,64) although no reduction were detected in the studies with other 
polyphenol extracts(66,67). In addition, one of the interventions with resveratrol and the 
HSE showed a reduction in serum total- and LDL-cholesterol(64) and NEFA(66). A 
significant reduction in the homeostasis model assessment insulin resistance index 
(HOMA-IR) associated with lower serum glucose levels following resveratrol 
supplementation was also reported(64). The clinical trials using the bayberry juice and 
resveratrol reported anti-inflammatory effects, with a reduction in serum cytokines 
(TNFα, IL-6 and IL-8)(63,64,67) and increased serum adiponectin levels(64). In addition, 
one of the intervention with resveratrol reported a reduction in NF-κB activity in the 
peripheral blood mononuclear cells(63).  
None of the clinical trials conducted liver biopsies and therefore had histological data 
on the severity of NAFLD. Instead non-invasive approaches such as semi-quantitative 
liver ultrasound examinations were carried out. Employing  this approach, Chang et al., 
reported that HSE supplementation significantly reduced (by about 15%) liver score 
damage(66) and among the clinical trial with resveratrol, only the one accompanied with 
a change in the lifestyle observed a significantly reduction in steatosis(63,64). Finally, the 
non-beneficial effect of resveratrol observed at the higher supplementation dose(65) is 
likely due to a hormesis phenomenon, characterized by a low-dose stimulation and 
inhibition and a potentially detrimental effect at high-dose, which has been described 
for a number bioactive compounds including resveratrol(68).   
 
Doses of polyphenols: from animals studies to clinical trials  
As discussed above, animal studies have been widely employed to assess the effects of a 
variety of polyphenols in NAFLD. However, the majority of these studies have used 
supra-physiological doses of compounds which are often found in low concentrations in 
the diet, with little consideration given to human equivalent doses.(69) Taking resveratrol 
as an example, most of the pre-clinical studies in rats have employed doses ranging 
from 10 to 100 mg/kg of body weight. Following allometric scaling calculations(69), 
such doses would equate to 97 and 970 mg of resveratrol for a 60 kg person. It should 
be pointed out that resveratrol is present in the diet in low amounts, with an estimated 
consumption in humans of about 0.93mg/day(70). Therefore from a dose perspective the 
majority of the rodent scientific literature provides little insight into the likely benefits 
of dietary sourced resveratrol in human NAFLD, although such higher doses may be 
achievable through the consumption of resveratrol rich supplements.  
However, the estimated intake of total polyphenols in Western populations is about 1-2 
g/day with other polyphenols occurring in much higher amounts in the diet than 
resveratrol(71), with most plant sources comprised of a combination of different 
compounds which collectively may have a much greater impact on liver health relative 
to the effect of each one in isolation. Thus, more studies assessing possible additive and 




NAFLD is the major cause of chronic liver disease in Western countries and currently 
about 2-5% of the population have NASH which is predicted to double by 2050(72,73). 
As NAFLD is essentially a condition of over-nutrition, and as there is a current lack of 
effective therapies there is a great need to identify dietary approaches for NAFLD 
prevention and treatment. Taken together, the current cell and animal evidence suggests 
that a number of polyphenols could prevent steatosis and its progression to NASH. The 
mechanisms underlying such observations are likely to include improved adipokine 
regulation and insulin sensitivity, a decline in de novo lipogenesis (via SREBP-1c) and 
an increase in FA β-oxidation activity which would reduce the lipid load in the liver. 
Recent insights have proposed that the activation of AMPK/SIRT-1 axis is the common 
trigger for the regulation of all these molecular processes. However, more experiments 
are required to verify this hypothesis. In addition, the antioxidant and anti-inflammatory 
effect exerted by polyphenols are also likely to make a significant contribution to the 
amelioration of NAFLD. But to date results from clinical studies are limited and often 
shown a subtle effect in comparison to animal models. Further research in rodents and 
humans using dietary achievable doses of individual polyphenols or select combinations 
are needed.    
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Figure 1: Polyphenol structures.  
 
Figure 2: Possible mechanisms underlying the preventative effect of polyphenols in 
NAFLD. Polyphenols may prevent cellular damage in hepatocytes associated with 
NAFLD through different mechanism of action including: a) reducing de novo 
lipogenesis through SREBP-1c down-regulation, b) increasing β-fatty acid oxidation by 
PPAR-α up-regulation, c) improving insulin sensitivity d) reducing oxidative stress 
through increasing the antioxidant defence levels via Nrf2, e) attenuating the 
inflammatory pathways. Presumably SREBP-1c down-regulation and PPAR-α up-
regulation are modulated by AMPK activation (by phosphorylation). TNFR, TNFα 
receptor; IL6-R, IL-6 receptor; IR, insulin receptor; FA, fatty acids; CD36, cluster of 
differentiation 36/FA translocase; p-AMPK, phosphorylated AMP-activated protein 
kinase α; SREBP-1c, sterol regulatory element-binding protein 1c; ACC, acetyl-CoA 
carboxylase; FAS, fatty acid synthase; SCD, stearoyl-CoA desaturase; GPAT, glycerol-
3-phosphate acyltransferase; CPT-1, carnitine palmitoyl transferase 1; ACO, acyl-
Coenzyme A; PGC-1, PGC1α, PPAR-γ coactivator-1α; Nrf2, nuclear factor-erythroid 2-
related factor 2; JNK, c-Jun N-terminal kinase; PKC, protein kinase C; mTOR, 
mammalian target of rapamycin. 
 
